NEW YORK, NY / ACCESSWIRE / May 30, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Volta Inc. (NYSE: VLTA)
Class Period: August 2, 2021 - March 28, 2022
Lead Plaintiff Deadline: May 31, 2022
Volta Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Volta had improperly accounted for restricted stock units issued in connection with the business combination of Volta Industries, Inc. ("Legacy Volta") and Tortoise Acquisition Corp. II; (2) as a result, the Company had understated its net loss for third quarter 2021; (3) there were material weaknesses in the Company's internal control over financial reporting that resulted in a material error; (4) as a result of the foregoing, the Company would restate its financial statements; (5) as a result of the foregoing, Legacy Volta's founders would imminently exit the Company; (6) as a result, the Company's financial results would be adversely impacted; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in VLTA: https://www.kleinstocklaw.com/pslra-1/volta-inc-loss-submission-form?id=27848&from=1
AbbVie Inc. (NYSE: ABBV)
Class Period: April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline: June 6, 2022
The ABBV lawsuit alleges AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.
Learn about your recoverable losses in ABBV: https://www.kleinstocklaw.com/pslra-1/abbvie-inc-loss-submission-form-2?id=27848&from=1
Amazon.com, Inc. (NASDAQ: AMZN)
Class Period: February 1, 2019 - April 5, 2022
Lead Plaintiff Deadline: July 5, 2022
The complaint alleges Amazon.com, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Amazon engaged in anticompetitive conduct in its private-label business practices, including giving Amazon products preference over those of its competitors and using third-party sellers' non-public data to compete with them; (ii) the foregoing exposed Amazon to a heightened risk of regulatory scrutiny and/or enforcement actions; (iii) Amazon's revenues derived from its private-label business were in part the product of impermissible conduct and thus unsustainable; and (iv) as a result, the defendants' public statements throughout the class period were materially false and/or misleading.
Learn about your recoverable losses in AMZN: https://www.kleinstocklaw.com/pslra-1/amazon-com-inc-loss-submission-form?id=27848&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE : The Klein Law Firm
View source version on accesswire.com: